Please login to the form below

gemcitabine

This page shows the latest gemcitabine news and features for those working in and with pharma, biotech and healthcare.

CTI slumps as Servier-partnered lymphoma drug fails

gemcitabine in aggressive B-cell NHL, but found that CTI’s drug was unable to improve progression-free survival (PFS), its primary endpoint.

Latest news

NICE knocks-back Shire's pancreatic cancer drug Onivyde

The watchdog was reviewing the treatment’s use in England and Wales for metastatic pancreatic cancer that has progressed after gemcitabine-based therapy.
Ipsen buys cancer business from stripped down Merrimack

For the tens of thousands of patients living with pancreatic cancer in the US who have received prior treatment with gemcitabine, Onivyde represents an important, differentiated innovation, given its proven overall
Shire wins EU licence for pancreatic cancer drug Onivyde

following treatment with Lilly's Gemzar (gemcitabine).
HIV prevention pill heads July CHMP recommendations

in adults whose disease has progressed after gemcitabine-based therapy.
Wales backs NHS use of Abraxane despite NICE rejection

gemcitabine for previously-untreated metastatic pancreatic cancer.

More from news
Approximately 1 fully matching, plus 57 partially matching documents found.

Latest Intelligence

The rise of chronic disease in BRIC markets

For late-stage patients, Brazil physicians are more likely to use an anthracycline-based regimen without a taxane in the first line, gemcitabine, paclitaxel or a combination of both in the

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Marketing strategy in complex environments

cells. A good example of this is the combined use of Abraxane and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas – Abraxane helps to inhibit cancer cell growth, and ... gemcitabine encourages apoptosis of cell DNA.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Manager, Healthcare Communications: £32, 000 - £40, 000 benefits

Project / Account Manager (Medical Education): Salary TBC

Director – Head of Public Affairs: Neg

Account Director - Digital: Great salary and benefits

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Senior Account Manager - Med Comms: Highly Competitive Salary &Benefits

Account Director: Negotiable

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Experienced Editor, London, Medical Communications: Competitive package

Healthcare Advertising Account Manager / Senior AM / AD: Salary TBC

Associate Medical Director: Highly Competitive

Account Manager, Healthcare Advertising: Salary TBC

Senior Medical Writer (Remote Working): Competitive Salary Offered

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Scientific Team Lead: Competitive Salary

Account Manager- Manchester, Macclesfield or Glasgow: Negotiable

Senior Account Executive – Medical Communications: Salary TBC

Medical Strategic Director, Healthcare Advertising Agency: Salary TBC

Director Healthcare PR Communications: Salary TBC

Associate Medical Director: Salary TBC

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Scientific Director: Highly Competitive Salary &Benefits

Editorial Director – Medical Education: Neg

Subscribe to our email news alerts

PMHub

Add my company

Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies: Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?: Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds: A vision of Paris as Europe’s leading hub for life sciences innovation...